Roche and AbbVie Push Towards First-Line CLL Treatment

Roche’s Genentech and AbbVie announced positive results from their Phase III CLL14 clinical trial.

The study evaluated fixed-duration the two companies’ Venclexta/Venclyxto (venetoclax) in combination with Genentech’s Gazyva/Gazyvaro (obinutuzumab) in patients with previously untreated chronic lymphocytic leukemia (CLL) and co-existing medical conditions.